cic in sarcoidosis

5
Thorax, 1980, 3 5 , 286-289 Circulating immune complexes i n N M c I JOHNSON, M W McNICOL, J E BURTON-KEE, AN D J F MOWBRAY From t h e Cardiothoracic Department, Central Middlesex Hospital, t h e Willesden Chest Clinic, a n d t he Department o f Experimental Pathology, S t Mary's Hospital Medical School, London ABSTRACT T h e sera o f 5 0 patients with sarcoidosis were tested f o r t h e presence o f circulating complexes using polyethylene glycol precipitation, followed b y single radial immuno diffusion f o r the amounts o f Clq, JgG, IgM, a n d double diffusion f o r the presence o f IgA. Complexes were detected i n 2 9 ( 5 8 % ) patients. No correlation could be found between t he presence o f these complexes a n d t h e length o f history, stage, or activity o f disease, n o r t o steroid therapy. Rheumatoid factor w a s detected i n 14 patients ( 2 8 % ) , 1 3 o f whom had circulating immune complexes, a n d 1 2 o f whom h a d active disease. Total serum C 3 , CH50, a n d C l q were normal, as were immunoglobulin levels. I n patients with extrathoracic sarcoidosis, especially skin o r joint involvement, complexes were commonly found. T he aetiological significance of these complexes remains uncertain. Circulating immune complexes occur i n some patients with sarcoidosis, th e proportion varying between 3 % and 5 1 % depending o n t h e technique used. 1 5 Th e rode o f immune complexes i n sarcoidosis i s uncertain. W e have investigated sera from a n unselected group o f patien,ts with sarcoidosis f o r t h e presence a n d composition o f immune complexes t o s e e whether these com- plexes were associated with active o r progressive sarcoidosis, a s might b e expected i f these com- plexes a re o f pathogenic significance. Methods Fifty patients with sarcoidosis were studied ( 3 2 male, 1 8 female). There were t h e first 5 0 t o b e seen a t Willesden Chest Clinic o r Central Middlesex Hospital during t h e period o f this study. T h e mean a g e w a s 4 0 years (range 17-63 yr). Twenty-eight were black, 1 6 white, an d s x Indian. Length of history ranged from less than on e month t o over 2 0 years (mean 4 9 yr). A diagnosis of sarcoidosis w a s made o n clinical features a n d t h e result o f Kveim testing, lung, mediastinal, lymph node, skin, o r liver biopsies i n a l l cases coupled with characteristic radiographic abnormalities. Other causes f o r non-caseating granulomata were excluded a s f a r a s possible. A n assessment o f whether t h e disease w a s active o r n ot w a s made at the time o f th e patient's visit Address f or reprint requests: Dr N M cI Johnson, Medical Unit, Middlesex Hospital, Mortimer Street, London W I . o n basis o f clinical, biochemical, o r radio- logical features. A t t h e e n d o f t h e study t h e chest radiographs taken o n t he same d a y a s the blood samples were assessed f o r t h e presence o f lym- phadenopathy, infiltration, or fibrosis without t h e observer having reference t o t h e patient's name or clinical details. Th e standard staging o f sar- coidosis w a s made: 0=normal chest film; 1 = bilateral hilar adenopathy, alone; 2=bilateral hilar adenopathy plus pulmonary infiltration; 3 = pulmonary infiltration o r fibrosis alone. Control sera f o r serum immunoglobin and complement levels were taken from 5 0 healthy individuals. F o r t h e polyethylene glycol preci- pitation, these sera a n d aliquots from a pool o f more than 2 0 normal people were used ( 8 0 estimations i n all). Th e assay involved t h e precipitation o f soluble immune complexes from serum b y th e addition o f polyethylene glycol, molecular weight 6000 (PEG), a modification of t h e method described b y Nydegger.6 Th e amounts of Clq, IgG, a n d I g M i n the precipitate were measured directly b y single radial immunodiffusion (SRID) a n d t h e presence o f I g A w a s determined b y double dif- fusion. T h e values were compared with those obtained i n this test from normal sera. A solution (0ff1 ml ) o f 1 2 % PE G i n barbitone- buffered saline containing 6 0 m M EDTA, p H 7 6 , w a s mixed with 0 - 5 m l of the test serum, used either fresh or after storage a t -70°C, an d left f o r 1 8 hours a t +4'C. T h e precipitated immune complexes were separated from the serum, b y 2 8 6

Upload: bumdin

Post on 06-Apr-2018

219 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: CIC in Sarcoidosis

8/3/2019 CIC in Sarcoidosis

http://slidepdf.com/reader/full/cic-in-sarcoidosis 1/4

T h o r a x , 1 9 8 0 , 3 5 , 2 8 6 - 2 8 9

C i r c u l a t i n g i m m u n e c o m p l e x e s i n s a r c o i d o s i sN McI JOHNSON, MW McNICOL, J E BURTON-KEE, AND J F MOWBRAY

F r o m t h e C a r d i o t h o r a c i c D e p a r t m e n t , C e n t r a l M i d d l e s e x H o s p i t a l , t h e W i l l e s d e n C h e s t C l i n i c , a n d t h eD e p a r t m e n t o f E x p e r i m e n t a l P a t h o l o g y , S t M a r y ' s H o s p i t a l M e d i c a l S c h o o l , L o n d o n

ABSTRACT T h e sera o f 5 0 p a t i e n t s w i t h s a r c o i d o s i s we r e t e s t e d f o r t h e pr e s enc e o f c i r c u l a t i n gi m m u n e c o m p l e x e s u s i n g p o l y e t h y l e n e g l y c o l p r e c i p i t a t i o n , f o l l o w e d b y s i n g l e r a d i a l immunod i f f u s i o n f o r t h e amounts o f C l q , J g G , I g M , a n d d o u b l e d i f f u s i o n f o r t h e presence o f I g A . C o m p l e x e swere d e t e c t e d i n 2 9 ( 5 8 % ) p a t i e n t s . No c o r r e l a t i o n c o u l d b e f o u n d b e t w e e n t h e pre s ence o f t h e s ec o m p l e x e s a n d t h e l e n g t h o f h i s t o r y , s t a g e , o r a c t i v i t y o f d i s e a s e , no r t o s t e r o i d t h e r a p y . R h e u m a t o i df a c t o r wa s d e t e c t e d i n 1 4 p a t i e n t s ( 2 8 % ) , 1 3 o f whom h a d c i r c u l a t i n g i m m u n e c o m p l e x e s , a n d 1 2

o f whom h a d a c t i v e d i s e a s e . T o t a l s e r u m C 3 , C H 5 0 , a n d C l q w e r e n o r m a l , a s w e r e i m m u n o g l o b u l i nl e v e l s . I n p a t i e n t s w i t h e x t r a t h o r a c i c s a r c o i d o s i s , e s p e c i a l l y s k i n o r j o i n t i n v o l v e m e n t , c o m p l e x e sw e r e c o m m o n l y f o u n d . The a e t i o l o g i c a l s i g n i f i c a n c e o f t h e s e c o m p l e x e s r e m a i n s u n c e r t a i n .

C i r c u l a t i n g i m m u n e c o m p l e x e s o c c u r i n s o m ep a t i e n t s w i t h s a r c o i d o s i s , t h e p r o p o r t i o n v a r y i n gb e t w e e n 3% a n d 5 1 % d e p e n d i n g o n t h e t e c h n i q u eu s e d . 1 5 T h e r o d e o f immune c o m p l e x e s i ns a r c o i d o s i s i s u n c e r t a i n . We h a v e i n v e s t i g a t e ds e r a f r o m a n u n s e l e c t e d g r o u p o f p a t i e n , t s w i t hs a r c o i d o s i s f o r t h e p r e s e n c e a n d c o m p o s i t i o n o f

immune c o m p l e x e s t o s e e w h e t h e r t h e s e c o m -p l e x e s w e r e a s s o c i a t e d w i t h a c t i v e o r p r o g r e s s i v es a r c o i d o s i s , a s m i g h t b e e x p e c t e d i f t h e s e com-

p l e x e s a r e o f p a t h o g e n i c s i g n i f i c a n c e .

M e t h o d s

F i f t y p a t i e n t s w i t h s a r c o i d o s i s w e r e s t u d i e d( 3 2 m a l e , 1 8 f e m a l e ) . T h e r e w e r e t h e f i r s t 5 0 t o

b e s e e n a t W i l l e s d e n C h e s t C l i n i c o r C e n t r a lM i d d l e s e x H o s p i t a l d u r i n g t h e p e r i o d o f t h i ss t u d y . T h e m e a n a g e w a s 4 0 y e a r s ( r a n g e 1 7 - 6 3

y r ) . T w e n t y - e i g h t w e r e b l a c k , 1 6 w h i t e , a n d s i xI n d i a n . L e n g t h o f h i s t o r y r a n g e d f r o m l e s s t h a no n e m o n t h t o o v e r 2 0 y e a r s ( m e a n 4 9 y r ) . Ad i a g n o s i s o f s a r c o i d o s i s w a s made o n c l i n i c a lf e a t u r e s a n d t h e r e s u l t o f K v e i m t e s t i n g , l u n g ,m e d i a s t i n a l , l y m p h n o d e , s k i n , o r l i v e r b i o p s i e s i na l l c a s e s c o u p l e d w i t h c h a r a c t e r i s t i c r a d i o g r a p h i ca b n o r m a l i t i e s . O t h e r c a u s e s f o r n o n - c a s e a t i n gg r a n u l o m a t a w e r e e x c l u d e d a s f a r a s p o s s i b l e .An a s s e s s m e n t o f w h e t h e r t h e d i s e a s e w a s a c t i v eo r n o t w a s made a t t h e t i m e o f t h e p a t i e n t ' s v i s i t

A d d r e s s f o r r e p r i n t r e q u e s t s : Dr N M c I J o h n s o n , M e d i c a l U n i t ,M i d d l e s e x H o s p i t a l , M o r t i m e r S t r e e t , London W I .

o n t h e b a s i s o f c l i n i c a l , b i o c h e m i c a l , o r r a d i o -l o g i c a l f e a t u r e s . A t t h e e n d o f t h e s t u d y t h e c h e s t

r a d i o g r a p h s t a k e n o n t h e s a m e d a y a s t h e b l o o d

s a m p l e s w e r e a s s e s s e d f o r t h e p r e s e n c e o f l y m -p h a d e n o p a t h y , i n f i l t r a t i o n , o r f i b r o s i s w i t h o u t t h e

o b s e r v e r h a v i n g r e f e r e n c e t o t h e p a t i e n t ' s nameo r c l i n i c a l d e t a i l s . T h e s t a n d a r d s t a g i n g o f s a r -

c o i d o s i s w a s m a d e : 0 = n o r m a l c h e s t f i l m ; 1=b i l a t e r a l h i l a r a d e n o p a t h y , a l o n e ; 2 = b i l a t e r a lh i l a r a d e n o p a t h y p l u s p u l m o n a r y i n f i l t r a t i o n ; 3=p u l m o n a r y i n f i l t r a t i o n o r f i b r o s i s a l o n e .

C o n t r o l s e r a f o r s e r u m i m m u n o g l o b i n a n dc o m p l e m e n t l e v e l s w e r e t a k e n f r o m 5 0 h e a l t h yi n d i v i d u a l s . F o r t h e p o l y e t h y l e n e g l y c o l p r e c i -p i t a t i o n , t h e s e s e r a a n d a l i q u o t s f r o m a p o o l o fm o r e t h a n 2 0 n o r m a l p e o p l e w e r e u s e d ( 8 0e s t i m a t i o n s i n a l l ) .

The a s s a y i n v o l v e d t h e p r e c i p i t a t i o n o f s o l u b l e

immune c o m p l e x e s f r o m s e r u m b y t h e a d d i t i o n

o f p o l y e t h y l e n e g l y c o l , m o l e c u l a r w e i g h t 6 0 0 0( P E G ) , a m o d i f i c a t i o n o f t h e m e t h o d d e s c r i b e d b yN y d e g g e r . 6 T h e a m o u n t s o f C l q , I g G , a n d IgMi n t h e p r e c i p i t a t e w e r e m e a s u r e d d i r e c t l y b ys i n g l e r a d i a l i m m u n o d i f f u s i o n ( S R I D ) a n d t h ep r e s e n c e o f I g A w a s d e t e r m i n e d b y d o u b l e d i f -f u s i o n . T h e v a l u e s w e r e c o m p a r e d w i t h t h o s eo b t a i n e d i n t h i s t e s t f r o m n o r m a l s e r a .A s o l u t i o n ( 0 f f 1 m l ) o f 12% PEG i n b a r b i t o n e -

b u f f e r e d s a l i n e c o n t a i n i n g 6 0 mM EDTA, pH 7 6 ,w a s m i x e d w i t h 0 - 5 m l o f t h e t e s t s e r u m , u s e de i t h e r f r e s h o r a f t e r s t o r a g e a t - 7 0 ° C , a n d l e f tf o r 1 8 h o u r s a t + 4 ' C . T h e p r e c i p i t a t e d immune

c o m p l e x e s w e r e s e p a r a t e d f r o m t h e s e r u m , b y2 8 6

Page 2: CIC in Sarcoidosis

8/3/2019 CIC in Sarcoidosis

http://slidepdf.com/reader/full/cic-in-sarcoidosis 2/4

C i r c u l a t i n g immune c o m p l e x e s i n s a r c o i d o s i s

c e n t r i f u g i n g a t 1000 g f o r 2 0 m i n u t e s a t +40C,

a n d w a s h e d o n c e i n 2 ml o f 2 % PEG i n b a r b i -t o n e - b u f f e r e d s a l i n e c o n t a i n i n g 1 0 mM EDTA,pH 7 - 6 . The t u b e s were d r a i n e d b r i e f l y , t h e preci-

p i t a t e s d i s s o l v e d i n 0 5 ml b a r b i t o n e b u f f e r e d

s a l i n e , m i x e d w e l l , a n d l e f t f o r 3 0 m i n u t e s b e f o r ea s s a y i n g f o r I g G , I g M , I g A , a n d C l q .

The c o n c e n t r a t i o n s o f C l q , I g G , a n d I gM i nt h e PEG p r e c i p i t a t e a n d C l q , I g G , I g M , a n d IgA

i n t h e s t a r t i n g serum w e r e d e t e r m i n e d b y SRID

i n 1 mm t h i c k g e l s o f 1% a g a r o s e i n 4 0 mMEDTA b a r b i t o n e - b u f f e r e d s a l i n e , pH 8 - 6 . The

pr e s e n c e o r a b s e n c e o f IgA i n t h e p r e c i p i t a t e was

s h o w n b y d o u b l e d i f f u s i o n , a g a i n s t m o n o s p e c i f i c

a n t i s e r u m .

E a c h b a t c h o f s e r a t e s t e d c o n t a i n e d a t l e a s ttwo c o n t r o l s e r a . The v a l u e s o b t a i n e d f r o m t h e s e

s e r a h a v e p r o v i d e d t h e c o n f i d e n c e l i m i t s f o r t h et e s t . S o l u b l e immune c o m p l e x e s w e r e d e e m e d t o

b e p r e s e n t i f IgA was p r e s e n t ( l o w e r l i m i t o f

s e n s i t i v i t y 2 1 g g / m l ) , o r i f any o f t h e components

a s s a y e d w e r e > mean + 2 SD o b t a i n e d f r o m t h e

c o n t r o l v a l u e s . T h e s e were as f o l l o w s : C l q >104

I L g / m l ( m e a n 4 4 j . g / m l + 6 0 j u g / m l ; I g G >69

i . g / m l ( m e a n 3 9 , g / m l + 3 0 u g / m l ) ; a n d IgM >

1 1 4 u g / m l ( 4 4 , g / m l + 7 0 i g / m l ) . M e a s u r e m e n t

o f s u p e r n a t a n t C l q a l l o w s d e t e c t i o n o f c o m p l e x e s

w h i c h b i n d a l l t h e a v a i l a b l e C l q . None was f o u n d

i n t h i s s e r i e s .

CH50was m e a s u r e d b y a s t a n d a r d f un c t io n a l

a s s a y , u s i n g s e n s i t i s e d s h e e p r e d c e l l s , a n d C3 b y

S R I D . The s e r a u s e d we r e r a i s e d i n r a b b i t s b y

i m m u n i s a t i o n w i t h p u r i f i e d c o m p o n e n t s , a n d

s t a n d a r d i s e d b y c o m p a r i s o n w i t h r e f e r e n c e a n t i -s e r a .

IgG r h e u m a t o i d f a c t o r wa s a s s a y e d b y a l a t e x

g l o b u l i n r e a g e n t ( R A - t e s t l a t e x - g l o b u l i n , H y l a n d ) .

R e s u l t s

IMMUNE COMPLEXES

C i r c u l a t i n g immune c o m p l e x e s were f o u n d i n 2 9

p a t i e n t s ( 5 8 % ) . I n 1 6 sera t h e c o m p l e x e s con-

t a i n e d C l q , i n 2 0 I g G , 1 4 I g M , a n d 1 5 I g A . No

c o r r e l a t i o n was f o u n d d b e t w e e n presence o f c i r -c u l a t i n g i m m un e c o m p l e x e s a n d t h e a ge o r s e x o f

t h e p a t i e n t .T h e r e was no s i g n i f i c a n t c o r r e l a t i o n b e t w e e n

t h e l e n g t h o f d i s e a s e a n d t h e presence o f immune

c o m p l e x e s ( f i g 1 ) .

F o r t y p a t i e n t s we r e c o n s i d e r e d t o h a v e a c t i v ed i s e a s e . T w e n t y - t h r e e o f t h e s e h a d c i r c u l a t i n gc o m p l e x e s , t h u s s h o w i n g no s i g n i f i c a n t c o r r e l a -t i o n . The c o m p o s i t i o n o f immune c o m p l e x e s i n

r e l a t i o n t o a c t i v i t y o f d i s e a s e i s shown i n f i g 2 .I n a d d it io n t o t h i s 1 3 o f 1 5 p a t i e n t s w i t h IgA

2 8 7

1 3

10

0

0

.0

E

z

. 0

r t o 2 3 4 5 6

D u r a t i o n o f d i s e a s e ( y r )

7 8 9 > 9

F i g 1 P r e s e n c e o f immune c o m p l e x e s i n s e r a f r o m5 0 p a t i e n t s w i t h a v a r y i n g l e n g t h o f h i s t o r y o f

s a r c o i d o s i s . D a r k a r e a r e p r e s e n t s t h e n u m b e r o fp a t i e n t s w i t h immune c o m p l e x e s , i n e a c h y e a r g r o u p .

c o m p l e x e s h a d a c t i v e d i s e a s e .S t e r o i d t h e r a p y h a d no s i g n i f i c a n t e f f e c t u p o n

t h e p r e s e n c e o f i m m u n e c o m p l e x e s ( f i g 2 ) .No c o r r e l a t i o n b e t w e e n t h e p r e s e n c e o f

immune c o m p l e x e s a n d s t a g e o f d i s e a s e w a s

f o u n d ( t a b l e 1 ) .N i n e o f t h e 1 4 p a t i e n t s w i t h e x t r a t h o r a c i c

s a r c o i d o s i s h a d c o m p l e x e s . A l l t h r e e p a t i e n t s w i t h

a r t h r i t i s a n d s i x o f t h e s e v e n p a t i e n t s w i t h s k i n

o r n a s a l i n v o l v e m e n t h a d c o m p l e x e s ,w h e r e a s

n o n e o f t h e t h r e e p a t i e n t s w i t h e y e i n v o l v e m e n t ,

a n d o n l y f o u r o f t h e s e v e n p a t i e n t s w i t h g r a n u -

l o m a t o u s h e p a t i t i s h a d e v i d e n c e o f c i r c u l a t i n gimmune c o m p l e x e s .

T a b l e 1 Immune c o m p l e x e s a n d s t a g e o f s a r c o i d o s i s

N u m b e r N u m b e r w i t h T y p e o f c o m p l e x R h e u m a t o i d

p a t i e n t s C l q I g G IgM I g A f a c t o r

S t a g e 0 1 0 6 5 5 4 1 2

S t a g e 1 1 3 6 2 4 3 3 3

S t a g e 2 1 9 1 1 6 9 6 7 6

S t a g e 3 8 6 3 2 1 4 3

5 0 2 9 1 6 2 0 1 4 1 5 1 4

I 5 w

Page 3: CIC in Sarcoidosis

8/3/2019 CIC in Sarcoidosis

http://slidepdf.com/reader/full/cic-in-sarcoidosis 3/4

N Mcl J o h n s o n , MW M c N i c o l , J E B u r t o n - K e e , a n d J F M o w b r a y

C l q

2 0 0

1 6 0 -

I g G I g M

+ - + - + -

D i s e a s e a c t i v i t y

F i g 2 C o m p o s i t i o n o f immune c o m p l e x e s i s o l a t e d f r o m t h e s e r a o f p a t i e n t s w i t h a c t i v e ( + ) , a n d n o t a c t i v e( - ) s a r c o i d o s i s . The h o r i z o n t a l b a r i n e a c h c o l u m n r e p r e s e n t s t h e u p p e r l i m i t o f n o r m a l (mean+2 SDs f o r

8 0 n o r m a l c o n t r o l s u b j e c t s ) o f 2 % PEG p r e c i p i t a b l e C l q , I g G , a n d I g M . T h e c l o s e d s y m b o l s (A * *)

r e p r e s e n t t h o s e p a t i e n t s o n s t e r o i d t h e r a p y , a n d o p e n s y m b o l s ( A 0 O) t h o s e n o t o n s t e r o i d t h e r a p y .

T a b l e 2 I m m u n o g l o b u l i n a n d c o m p l e m e n t l e v e l s i n5 0 p a t i e n t s w i t h s a r c o i d o s i s a n d 5 0 n o r m a l c o n t r o l

s u b j e c t sS e r u m S a r c o i d o s i s p a t i e n t s N o r m a l c o n t r o l s u b j e c t sp r o t e i n M e a n ± SD M e an ± SD

I g G 1 0 6 1 7 8 6 1 5

IgM 9 2 2 6 9 7 2 1

I g A 1 4 6 5 2 1 0 2 4 1

C l q 1 1 0 9 1 0 1 8CH50 9 9 9 1 0 6 7

C3 1 0 1 1 1 1 0 2 9

A l l l e v e l s a r e e x p r e s s e d a s a p e r c e n t a g e o f t h e n o r m a l t o t a l a m o u n t s .T h e r e a r e no s i g n i f i c a n t d i f f e r e n c e s b e t w e e n p a t i e n t s a n d c o n t r o l

s u b j e c t s .

RHEUMATOID FACTOR

R h e u m a t o i d f a c t o r was p r e s e n t i n 1 4 p a t i e n t s , 1 3o f whom h a d c i r c u l a t i n g i m m u n e c o m p l e x e s

( s e v e n C l q , e i g h t I g G , s e v e n I g M , e i g h t I g A ) .

T w e l v e o f t h e 1 4 h a d a c t i v e d i s e a s e .

COMPLEMENT AND I M M UNOGLOBULINS

CH50 a n d t h e s e r u m c o n c e n t r a t i o n s o f C l q , C 3 ,

I g G , I g M , a n d I g A d i d n o t d i f f e r s i g n i f i c a n t l yf r o m t h o s e o f n o r m a l c o n t r o l g r o u p ( t a b l e 2 ) .

D i s c u s s i o n

We h a v e f o u n d c i r c u l a t i n g i m m u n e c o m p l e x e su s i n g p r e c i p i t a t i o n w i t h 2 % PEG i n 58% o f

p a t i e n t s w i t h s a r c o i d o s i s . S e r u m l e v e l s o f i m -

m u n o g l o b u l i n s a n d c o m p l e m e n t c o m p o n e n t s w e r e

n o r m a l . We h a v e f o u n d n o c o r r e l a t i o n b e t w e e n

t h e p r e s e n c e o f immune c o m p l e x e s a n d d i s e a s ea c t i v i t y , l e n g t h o f h i s t o r y , o r r a d i o l o g i c a l e x t e n t

2 8 8

Page 4: CIC in Sarcoidosis

8/3/2019 CIC in Sarcoidosis

http://slidepdf.com/reader/full/cic-in-sarcoidosis 4/4

C i r c u l a t i n g i m m u n e c o m p l e x e s i n s a r c o i d o s i s

o f t h e d i s e a s e . T h e r e w a s a c o r r e l a t i o n b e t w e e ns k i n s a r c o i d o s i s a n d t h e p r e s e n c e o f immunec o m p l e x e s .

P r e v i o u s s t u d i e s h a v e d e s c r i b e d t h e p r e s e n c eo f c i r c u l a t i n g immune c o m p l e x e s i n u p t o 5 1 %

o f p a t i e n t s w i t h s a r c o i d o s i s . ' 1 5 Ou r r e s u l t s c o n -f i r m t h o s e o f G u p t a e t a 1 4 who u s e d t h e R a j i c e l la n d m o n o c l o n a l r h e u m a t o i d f a c t o r a s s a y whos u g g e s t e d t h a t b e t w e e n 5 0 a n d 60% o f p a t i e n t sw i t h s a r c o i d o s i s h a v e c i r c u l a t i n g i m m u n e com-

p l e x e s . I n s o m e s t u d i e s a n a s s o c i a t i o n b e t w e e ne r y t h e m a n o d o s u m a n d c i r c u l a t i n g i m m u n e com-

p l e x e s w a s n o t e d . ' 1 3 None o f o u r p a t i e n t s h a de r y t h e m a nodosum a t t h e t i m e o f t e s t i n g .

G u p t a e t a 1 4 f o u n d c i r c u l a t i n g i m m u n e com-

p l e x e s i n 1 7 o f 2 3 p a t i e n t s w i t h s t a g e 3 d i s e a s e .We h a d o n l y e i g h t p a t i e n t s w i t h s t a g e 3 d i s e a s e ,

s i x ( 7 5 % ) o f whom h a d c o m p l e x e s , b u t w i t h s u c hs m a l l n u m b e r s i t i s d i f f i c u l t t o d r a w f i r m c o n -

c l u s i o n s . A l l t h e i r p a t i e n t s w i t h s t a g e 1 o r s t a g e 2

d i s e a s e w i t h c i r c u l a t i n g immune c o m p l e x e s a l s oh a d e x t r a p u l m o n a r y f e a t u r e s o f s a r c o i d o s i s . How-e v e r i n o u r s t u d y , o f t h e 1 7 p a t i e n t s w i t h s t a g e 1

o r 2 d i s e a s e , t h e n i n e p a t i e n t s w i t h c i r c u l a t i n gi m m u n e c o m p l e x e s o n l y h a d i n t r a t h o r a c i c d i s -e a s e , a s d i d f i v e o f t h e s i x w h o s e c h e s t r a d i o g r a p ha t t h e t i m e o f t e s t i n g wa s n o r m a l .

Two p r e v i o u s . s t u d i e s ' 5 h a v e f o u n d a n a s s o c i a -t i o n b e t w e e n a c u t e s a r c o i d o s i s ( h i s t o r y l e s s t h a no n e y e a r ) a n d t h e p r e s e n c e o f i m m u n e c o m p l e x e s .We f a i l e d t o c o n f i r m t h i s . T h r e e o f o u r s e v e n

p a t i e n t s w i t h t h i s l e n g t h o f h i s t o r y d i d n o t h a v e

c o m p l e x e s . S i m i l a r l y , we f o u n d c o m p l e x e s i n 1 2

o f 2 1 p a t i e n t s w i t h c h r o n i c d i s e a s e ( m o r e t h a nf i v e y e a r s ) , w h e r e a s D a n i e l e e t a l a o n l y f o u n d

c o m p l e x e s i n t w o o f 1 0 s u c h p a t i e n t s . A l l t h e

p a t i e n t s o f H e d f o r s a n d N o r b e r g ' w i t h c i r c u l a t i n gc o m p l e x e s h a d a h i s t o r y o f one y e a r o r l e s s .L i k e o u r s e l v e s D a n i e l e e t a l 5 f o u n d no c o r r e l a -t i o n b e t w e e n t h e p r e s e n c e o f immune c o m p l e x e sa n d t h e s t a g e o f s a r c o i d o s i s .We h a v e c o n f i r m e d t h e a s s o c i a t i o n b e t w e e n

e x t r a t h o r a c i c s a r c o i d o s i s , e s p e c i a l l y s k i n o r j o i n td i s e a s e , a n d t h e p r e s e n c e o f c i r c u l a t i n g immunec o m p l e x e s . 4 5

2 8 9

S t e r o i d s w e r e g i v e n t o h a l f o u r p a t i e n t s , m o s to f whom h a d immune c o m p l e x e s . I t i s a r g u a b l et h a t t h e u s e o f s t e r o i d s m a y h a v e e l i m i n a t e d t h ec o m p l e x e s i n a f u r t h e r s i x p a t i e n t s ; h o w e v e r t h i sw o u l d n o t h a v e a f f e c t e d o u r c o n c l u s i o n s .

T h e h i g h p r e v a l e n c e o f r h e u m a t o i d f a c t o r i np a t i e n t s w i t h a c t i v e d i s e a s e s u g g e s t s t h a t t h ep r e s e n c e o f immune c o m p l e x e s a c t s a s a n a n t i -g e n i c s t i m u l u s f o r i t s p r o d u c t i o n . I t i s n o ts u r p r i s i n g t h a t G u p t a e t a l , 4 u s i n g m o n o c l o n a lr h e u m a t o i d f a c t o r r a d i o i m m u n o a s s a y , d e t e c t e dt h i s g r o u p o f p a t i e n t s .

I f immune c o m p l e x e s a r e o f p a t h o g e n i c s i g n i -f i c a n c e i n s a r c o i d o s i s t h e y s h o u l d b e e x p e c t e d t ob e p r e s e n t i n t h e a c u t e d i s e a s e a n d c l e a r e d a s t h ed i s e a s e r e s o l v e s . The p e r s i s t e n c e o f s u c h c o m -p l e x e s s h o u l d i m p l y a c t i v e o r p r o g r e s s i v e d i s e a s e .

Our r e s u l t s f a i l t o s u b s t a n t i a t e t h i s h y p o t h e s i s a n dt h e a e t i o l o g i c a l s i g n i f i c a n c e a n d c o n s t i t u t i o n o ft h e s e c o m p l e x e s r e m a i n s u n k n o w n .

R e f e r e n c e s

1 H e d f o r s E , N o r b e r g R . E v i d e n c e f o r c i r c u l a t i n gimmune c o m p l e x e s i n s a r c o i d o s i s . C l i n E x p e rImmunol 1 9 7 4 ; 1 6 : 4 9 3 - 6 .

2 J a m e s DG, N e v i l l e E , W a l k e r A . I m m u n o l o g yo f s a r c o i d o s i s . Am J M e d 1 9 7 5 ; 5 9 : 3 8 8 - 9 4 .

3 J o n e s J V , Cumming RH, A s p l i n CM, L a s z l o G ,W h i t e R J . E v i d e n c e f o r c i r c u l a t i n g immune

c o m p l e x e s i n e r y t h e m a n o d o s u m a n d e a r l y s a r -c o i d o s i s . Ann NY Acad S c 1 9 7 6 ; 2 7 8 : 2 1 2 - 9 .4 G u p t a RC, K u e p p e r s F , DeRemee RA, H u s t o n

KA, M c D u f f i e F C . P u l m o n a r y a n d e x t r a p u l -m o n a r y s a r c o i d o s i s i n r e l a t i o n t o c i r c u l a t i n gimmune c o m p l e x e s : a q u a n t i f i c a t i o n o f immunec o m p l e x e s b y t w o r a d i o i m m u n o a s s a y s . Am Re vR e s p i r D i s 1 9 7 7 ; 1 1 6 : 2 6 1 - 6 .

5 D a n i e l e R P , M c M i l l a n L J , D a u b e r J H , R o s s m a nM D. Immune c o m p l e x e s i n s a r c o i d o s i s : a c o r -

r e l a t i o n w i t h a c t i v i t y , a n d d u r a t i o n o f d i s e a s e .C h e s t 1 9 7 8 ; 7 4 : 2 6 1 - 4 .

6 N y d e g g e r UE, L a m b e r t P H , G e r b e r H , M i e s c h e rP A . C i r c u l a t i n g i m m u n e c o m p l e x e s i n t h e s e r u m

i n s y s t e m i c l u p u s e r y t h e m a t o s u s a n d i n c a r r i e r so f h e p a t i t i s B a n t i g e n . Q u a n t i t a t i o n b y b i n d i n g t or a d i o l a b e l l e d C l q . J C l i n I n v e s t 1 9 7 4 ; 5 4 : 2 9 7 - 3 0 9 .